TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Full Feeding, Dietary Supplement: Placebo | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids and Antioxidant Supplements; Assigned to Arm(s): 1, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3, 4
C: Intervention Type: DRUG; Name: low calorie, low nitrogen parenteral nutrition for patient with NRS score 3; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: trophic enteral feeds | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: trophic enteral feeds | Intervention Type: BEHAVIORAL; Name: trophic enteral feeds; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Options:
A: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
D: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Options:
A: Arm Label: EPANOVA; Type: EXPERIMENTAL; Interventions: Drug: Epanova® (omega-3 carboxylic acids) | Arm Label: Corn oil; Type: ACTIVE_COMPARATOR; Interventions: Drug: corn oil control | Intervention Type: DRUG; Name: Epanova® (omega-3 carboxylic acids); Assigned to Arm(s): EPANOVA | Intervention Type: DRUG; Name: corn oil control; Assigned to Arm(s): Corn oil
B: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
C: Intervention Type: BEHAVIORAL; Name: Dietary intake; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle factors; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Blood biomarkers; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Health; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: DNA; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Mental well-being; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.
Brief Summary: Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dietary counseling, placebo capsules for omega-3 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: No dietary counseling and omega-3 capsules | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega-3 capsules and dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: No dietary counseling and omega-3 capsules; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 capsules and dietary counseling; Assigned to Arm(s): 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary counseling, placebo capsules for omega-3; Assigned to Arm(s): 2
B: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo
C: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Teen Alcohol and Violence Prevention in the ER
Brief Summary: This study is designed to address both alcohol misuse and violence among adolescents ages 14-18 seeking care in an urban emergency department (ED). The study is a randomized controlled trial comparing the effectiveness of a combined Adapted Motivational Interviewing and Skills Training intervention, delivered either by a computer or by a counselor, and an informational handout control condition.


Options:
A: Arm Label: Screened Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Screened and Assessed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Motivational Intervention | Intervention Type: BEHAVIORAL; Name: Brief Motivational Intervention; Assigned to Arm(s): Intervention
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2
C: Arm Label: 1 Brief Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention | Arm Label: 2) Booster; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief alcohol intervention plus booster | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention; Assigned to Arm(s): 1 Brief Intervention | Intervention Type: BEHAVIORAL; Name: Brief alcohol intervention plus booster; Assigned to Arm(s): 2) Booster
D: Arm Label: EARLY; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing plus feedback | Arm Label: Video Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Video | Arm Label: Informational Brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Informational Brochure | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing plus feedback; Assigned to Arm(s): EARLY | Intervention Type: BEHAVIORAL; Name: Video; Assigned to Arm(s): Video Information | Intervention Type: BEHAVIORAL; Name: Informational Brochure; Assigned to Arm(s): Informational Brochure

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Teen Alcohol and Violence Prevention in the ER
Brief Summary: This study is designed to address both alcohol misuse and violence among adolescents ages 14-18 seeking care in an urban emergency department (ED). The study is a randomized controlled trial comparing the effectiveness of a combined Adapted Motivational Interviewing and Skills Training intervention, delivered either by a computer or by a counselor, and an informational handout control condition.


Options:
A: Intervention Type: BEHAVIORAL; Name: Brief Intervention (adaptation of motivational interviewing); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2
C: Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MI; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): MI
D: Arm Label: 1) assessment plus motivational interview; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: motivational interviewing | Intervention Type: BEHAVIORAL; Name: motivational interviewing; Assigned to Arm(s): 1) assessment plus motivational interview

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Teen Alcohol and Violence Prevention in the ER
Brief Summary: This study is designed to address both alcohol misuse and violence among adolescents ages 14-18 seeking care in an urban emergency department (ED). The study is a randomized controlled trial comparing the effectiveness of a combined Adapted Motivational Interviewing and Skills Training intervention, delivered either by a computer or by a counselor, and an informational handout control condition.


Options:
A: Arm Label: BMI-T; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BMI-T | Arm Label: BMI-C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BMI-C | Arm Label: DPB; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: BMI-T; Assigned to Arm(s): BMI-T | Intervention Type: BEHAVIORAL; Name: BMI-C; Assigned to Arm(s): BMI-C
B: Arm Label: 1) MI/Family Check-Up; Type: EXPERIMENTAL; Interventions: Behavioral: MI/Family Check-up | Arm Label: 2) MI only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MI only | Intervention Type: BEHAVIORAL; Name: MI/Family Check-up; Assigned to Arm(s): 1) MI/Family Check-Up | Intervention Type: BEHAVIORAL; Name: MI only; Assigned to Arm(s): 2) MI only
C: Arm Label: Information only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information only | Arm Label: sexual risk reduction intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Sexual risk reduction intervention | Arm Label: SRRI+ETOH; Type: EXPERIMENTAL; Interventions: Behavioral: sexual risk reduction + alcohol risk reduction component | Intervention Type: BEHAVIORAL; Name: Information only; Assigned to Arm(s): Information only | Intervention Type: BEHAVIORAL; Name: Sexual risk reduction intervention; Assigned to Arm(s): sexual risk reduction intervention | Intervention Type: BEHAVIORAL; Name: sexual risk reduction + alcohol risk reduction component; Assigned to Arm(s): SRRI+ETOH
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Resynchronization/Defibrillation for Ambulatory Heart Failure Trial
Brief Summary: Congestive heart failure (CHF) is a common health problem that leads to frequent hospitalizations and an increased death rate. In spite of advances in drug therapy, it remains a significant public health problem. Recently, a new therapy has been developed for advanced heart failure patients with a ventricular conduction abnormality. This new therapy, called cardiac resynchronization (CRT), is a device which stimulates the atrium, the right ventricle, and the left ventricle providing synchronization of the contraction of the heart chambers. It is the addition of this therapy to an implantable cardioverter defibrillator (ICD) that will be evaluated in this study. This study will compare whether the implantation of this new therapy device, in combination with an implantable cardioverter defibrillator, will reduce total mortality and hospitalizations for CHF.


Options:
A: Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy with & without defibrillator; Assigned to Arm(s): N/A
B: Arm Label: Biventricular pacing; Type: EXPERIMENTAL; Interventions: Device: Cardiac Resynchronization Therapy (CRT) | Arm Label: Right ventricular pacing; Type: ACTIVE_COMPARATOR; Interventions: Device: Cardiac Resynchronization Therapy (CRT) | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT); Assigned to Arm(s): Biventricular pacing | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT); Assigned to Arm(s): Right ventricular pacing
C: N/A
D: Arm Label: 1. Optimal Medical therapy plus ICD; Type: ACTIVE_COMPARATOR; Interventions: Device: Optimal Medical Therapy plus ICD | Arm Label: 2. Optimal Medical Therapy plus CRT/ICD; Type: ACTIVE_COMPARATOR; Interventions: Device: Optimal Medical Therapy plus CRT/ICD | Intervention Type: DEVICE; Name: Optimal Medical Therapy plus ICD; Assigned to Arm(s): 1. Optimal Medical therapy plus ICD | Intervention Type: DEVICE; Name: Optimal Medical Therapy plus CRT/ICD; Assigned to Arm(s): 2. Optimal Medical Therapy plus CRT/ICD

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: Arm Label: ENOXAPARIN 2 HOURS BEFORE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Arm Label: Enoxaparin 40 mg 12 hours before; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin 40 mg 2 hours before arm, Drug: Enoxaparin 40 mg 12 hours before arm | Intervention Type: DRUG; Name: Enoxaparin 40 mg 2 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before | Intervention Type: DRUG; Name: Enoxaparin 40 mg 12 hours before arm; Assigned to Arm(s): ENOXAPARIN 2 HOURS BEFORE, Enoxaparin 40 mg 12 hours before
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I
C: Arm Label: Prophylactic enexaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Therapeutic Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Prophylactic enexaparin, Therapeutic Enoxaparin
D: Arm Label: Active ECS; Type: ACTIVE_COMPARATOR; Interventions: Device: Knee-length, graduated elastic compression stocking | Arm Label: Placebo ECS; Type: PLACEBO_COMPARATOR; Interventions: Device: Knee-length, placebo stocking | Intervention Type: DEVICE; Name: Knee-length, graduated elastic compression stocking; Assigned to Arm(s): Active ECS | Intervention Type: DEVICE; Name: Knee-length, placebo stocking; Assigned to Arm(s): Placebo ECS

Answer: B